Advances in screening, diagnosis, and treatment of breast cancer

Mayo Clinic Proceedings

Volumn 79, Issue 6, 2004, Pages 810-816

  Mincey, Betty A ^a   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; CELECOXIB; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEMCITABINE; IRINOTECAN; IXABEPILONE; LETROZOLE; METHOTREXATE; PACLITAXEL; PEMETREXED; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TIPIFARNIB; TRASTUZUMAB; UNINDEXED DRUG;

BREAST CANCER; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE MARKER; ECHOGRAPHY; HIGH RISK PATIENT; HUMAN; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; SHORT SURVEY; UNITED STATES;

EID: 2542486358     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.6.810     Document Type: Short Survey

References (14)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Humphrey LL, Helfand M, Chan BKS, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(5, pt 1):347-360.
3. Smith RA, Saslow D, Andrews Sawyer K, et al, High-Risk Work Group, Screening Older Women Work Group, Mammography Work Group, Physical Examination Work Group, New Technologies Work Group, Breast Cancer Advisory Group. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003;53:141-169.
4. Mincey BA. Genetics and the management of women at high risk for breast cancer. Oncologist. 2003;8:466-473.
5. Boyd NF, Martin LJ, Stone J, Greenberg C, Minkin S, Yaffe MJ. Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention. Curr Oncol Rep. 2001;3:314-321.
6. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296-300.
7. Green FL, Page DL, Fleming ID, et al, American Joint Committee on Cancer, eds. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
8. Recht A. Integration of systemic therapy and radiation therapy for patients with early-stage breast cancer treated with conservative surgery. Clin Breast Cancer. 2003;4:104-113.
9. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001;93:979-989.
10. Mincey BA, Palmieri FM, Perez EA. Adjuvant therapy for breast cancer: recommendations for management based on consensus review and recent clinical trials. Oncologist. 2002;7:246-250.
11. Pritchard KI. The best use of adjuvant endocrine treatments. Breast. 2003;12:497-508.
12. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98:1802-1810.
13. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802.
14. Coombes RC, Hall E, Gibson LJ, et al, Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092.